GENE ONLINE|News &
Opinion
Blog

2020-03-22| COVID-19

Could Patients be Carriers of COVID-19 Post Recovery?

by Rajaneesh K. Gopinath
Share To

By Rituparna Ganguly, Ph.D.

Edited by Rajaneesh K. Gopinath, Ph.D.

A recently published research letter in JAMA is raising concerns after it reported four patients testing positive for the COVID-19 causing coronavirus, 5-13 days after their recovery. These patients, who are Chinese medical professionals contracted the disease through work-related exposure and were being treated at the Zhongnan Hospital at Wuhan University. Patients had a combination of fever and cough at the onset of the disease. Although their symptoms were mild to moderate, RT-PCR based diagnostic testing on throat swabs showed positive viral nucleotides and chest CT (Computed tomography) imaging demonstrated positive lesions in the lungs.

All four of them were treated with antiviral drug oseltamivir (same as the composition of Tamiflu) at a dose of 75 mg every 12 hours. The patients recovered from their infection in a span of 12-32 days on average. All clinical and radiological symptoms were resolved in 3 patients, while one continued to show signs of chest lesions. Before their hospital discharge, all of them tested negative for RT-PCR and were advised to remain under home quarantine for 5 additional days. Surprisingly, 5-13 days since their discharge, follow up RT-PCR tests came out positive in these patients. There was no indication of new exposures and family members were uninfected. Apart from the positive RT-PCR diagnosis, there were no other symptoms.

This interesting finding suggests that recovered COVID-19 patients might still be carriers and potentially infect others. This is unanticipated since patients show no signs of infection and cleared diagnostic testing and radiological evaluations. This case is not an anomaly since the Japanese health ministry also reported the first case in Japan where a 40-year-old woman patient tested positive after hospital discharge. Another report from China confirmed that 14% of COVID-19 survivors tested positive again. A similar observation was made in a study conducted in 10 COVID-19 positive children, where rectal swabs of five subjects confirmed viral presence long after their nasopharyngeal swabs or CT imaging turned negative. However, there was no evidence to show that the viruses retained were capable of replication.

The current pandemic is a stress test to the medical infrastructures around the world and hospital systems are overwhelmed with increasing patients as it is. A study published in The Lancet journal has reported that the longest observed time span for viral shedding in survivors is 37 days. At present, the discharge criteria of patients include no fever for 3 days, improved respiratory symptoms, two consecutive negative RT-PCR results, and improved lesions in CT imaging. This report indicates the importance of reevaluating follow-up protocols and calls for patient monitoring for a longer duration. More importantly, it is imperative to determine whether the residual viruses in the body after recovery are infectious, a piece of information that would help us flatten the curve.

Related Article: Purine Repressing Probiotic Might Halt COVID-19, says Korean Researchers

References
  1. https://jamanetwork.com/journals/jama/fullarticle/2762452
  2. https://www.nature.com/articles/s41591-020-0817-4
  3. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30566-3/fulltext#bib33
  4. https://www.theguardian.com/world/2020/feb/27/japanese-woman-tests-positive-for-coronavirus-for-second-time
  5. https://www.caixinglobal.com/2020-02-26/14-of-recovered-covid-19-patients-in-guangdong-tested-positive-again-101520415.html

 

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
CDC Warns Of “Tripledemic” Winter Amid Rising Flu And RSV Cases
2022-11-14
Sanofi, GSK Secure European COVID-19 Booster Approval, AstraZeneca Withdraws U.S. Application
2022-11-10
AstraZeneca’s COVID-19 Vaccine Finally Wins Full Authorization in the European Union
2022-11-01
LATEST
Rebyota Passes Through FDA To Become First Approved Fecal Microbiota Product
2022-12-05
RemeGen Presented New Data Updates on Telitacicept for SLE and primary Sjogren’s syndrome at ACR Convergence 2022
2022-12-05
EMA Urges Pholcodine’s Removal from European Market Following Safety Study
2022-12-05
Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis
2022-12-04
Cure Brain Cancer Foundation Rings Nasdaq Opening Bell, Announces U.S. Expansion
2022-12-02
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
2022-12-02
Pfizer To Invest $1.26 Billion In Irish Plant, Forms New Vant Company Targeting Inflammation
2022-12-02
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!